Bizarre Patents
A new toilet tank assembly aquarium for housing aquatic creatures.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7232580 | Use of extracts of for preparing a medicament intended to treat sarcopenia A method of treating sarcopenia in warm-blooded animals comprising administering to warm-blooded animals in need thereof an amount of an extract of Ginkgo biloba comprising from 5.5 to 8% in total of ginkgolides A, B, C and J, from 40 to 60% of flavoneglycosi... | 06/19/2007 |
| 7138148 | Use of extracts of for preparing a medicament intended to treat sarcopenia The invention concerns the use of Ginkgo biloba extracts, and in particular Ginkgo biloba extracts comprising 20 to 30% of flavoneglycosides, 2.5 to 4.5% in total of gingkolides A, B, C and J, 2 to 4% of bilobalide, less than 10% of proanthocyanidins a... | 11/21/2006 |
| 6596709 | 6-sulphanoyl-3-quinolylphosphonic acid compounds The invention relates to a compound of formula (I): ##STR1## wherein: X represents chlorine or fluorine or CF3, R represents hydrogen or a group ##STR2## and methods for using the same.... | 07/22/2003 |
| 6413968 | Treatment of myasthenia gravis by cyclic nucleotide phosphodiesterase inhibition A method of treating myasthenia gravis confined to the eyes iby administering, orally, a therapeutically effective dose the nucleotide (cGMP) phosphodiesterase inhibitor Sildenafil either 100 mg. once a day, or 25 mg. four times a day. The object of this ... | 07/02/2002 |
| 6261560 | Method for inhibiting muscle protein proteolysis with antibodies to interleukin-6 receptor The present invention provides a muscle protein proteolysis inhibiting agent comprising antibody to Interleukin-6 receptor (IL-6R antibody). Antibodies of animals other than humans such as mice and rats, chimeric antibodies of these antibodies with human ... | 07/17/2001 |
| 6060480 | Preventives/remedies for muscle tissue degenerations An agent for the prophylaxis or treatment of muscle tissue degeneration, containing, as an active ingredient, a quinoline compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt. The prophylactic or therapeutic agent of muscl... | 05/09/2000 |
| 5981536 | Use of xanthine derivatives for the modulation of apoptosis Compounds of the formula I ##STR1## where one of the radicals R1 and R3 is a radical of the formula II --(CH2)n --A--CH3 (II) in which A is a covalent bond,--C(O)-- or --C(R4)(OH)--, a... | 11/09/1999 |
| 5912005 | Methods of use of uncoated gel particles The invention covers a method of implanting a living donor cell into a host animal without inflammatory response or rejection of the donor cell by the host animal, by obtaining an uncoated particle of a biocompatible, temperature-independent gel that enca... | 06/15/1999 |
| 5856330 | Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin Compounds of the formula I ##STR1## where one of the radicals R1 and R3 is a radical of the formula II --(CH2)n --A--CH3 (II) in which A is a covalent bond, --C(O)-- or --C(R4)(OH)--, ... | 01/05/1999 |
| 5651980 | Methods of use of uncoated gel particles The invention covers a method of implanting a living donor cell into a host animal without inflammatory response or rejection of the donor cell by the host animal, by obtaining an uncoated particle of a biocompatible, temperature-independent gel that enca... | 07/29/1997 |
| 5552442 | Therapeutic applications of clenbuterol The present invention relates to therapeutic uses of clenbuterol in humans and animals. The uses include retarding or reversing muscular atrophy of denervated muscle, alleviating or reversing loss of function arising from surgical or accidental muscular t... | 09/03/1996 |
| 5541074 | Antibodies to dystrophin and uses therefor The invention relates to a muscular dystrophy (MD) probe comprising a substantially purified single-stranded nucleic acid sequence capable of hybridizing to a region of DNA on a human X chromosome between the deletion break point at Xp21.3 and the translo... | 07/30/1996 |
| 5541188 | Therapeutic applications of beta-adrenergic agonists The present invention relates to therapeutic uses of beta-adrenergic antagonists other than clenbuterol in humans and animals. The uses include retarding or reversing muscle disease such as muscular dystrophy, alleviating or reversing peripheral nervous s... | 07/30/1996 |
| 5530029 | Therapeutic applications of clenbuterol The present invention relates to therapeutic uses of clenbuterol in humans and animals. The uses include retarding or reversing muscle disease such as muscular dystrophy, alleviating or reversing peripheral nervous system disease, and alleviating or rever... | 06/25/1996 |
| 5434142 | Method of treatment for muscular dystrophy Administering to a patient of muscular dystrophy a pharmaceutical agent containing glycyrrhizin and/or a pharmaceutically acceptable salt thereof as effective components is effective against muscular dystrophy, particularly, Duchenne or Becker muscular dy... | 07/18/1995 |
| 5130141 | Compositions for and methods of treating muscle degeneration and weakness Compositions for and methods of treating muscle weakness and degeneration are described. Such compositions include myogenic cells which are administered by the described methods to one or more affected muscles.... | 07/14/1992 |
| 5070079 | Pharmaceutical compositions containing cytidine monophosphate of 5-acetamido-3-, 5-D-deoxy-D-glycero-D-galacto-nonulosamic acid The invention relates to pharmaceutical compositions for use in the therapy of pathological states related to disturbances of the nervous stimulus in the central (CNS) and peripheral (PNS) nervous system containing as an active substance the cytidine mono... | 12/03/1991 |
| 4885167 | Restoration of impaired cardiac function of patients with diverse muscular dystrophies by therapy with coenzyme Q10 The present invention relates to the use of Coenzyme Q in the treatment of slow muscle degeneration, commonly known to those of skill in the art so a dystrophy or atrophy, and the accompanying cardiac complications typically identified in such patients. A... | 12/05/1989 |
| 4741902 | Compositions for treatment of neurological and related disorders The invention provides compositions of matter having pharmacological activity and which are useful in the treatment of the symptoms of neurological and other disorders, particularly those disorders which are caused by malfunction of the immune mechanism. ... | 05/03/1988 |
| 4684520 | Pharmaceutical compositions having cerebral antianoxic and metabolic activities The invention relates to novel pharmaceutical compositions containing ubiquinone, particularly Coenzyme Q10, and mixtures of phospholipids having organic or vegetal origin, in weight-ratios ranging from 1/1 to 1/100,000, together with pharmaceu... | 08/04/1987 |
| 4677121 | Method of inhibiting muscle protein degradation Muscle protein breakdown or degradation may be reduced or inhibited in mammals, particularly humans recovering from surgery or suffering from a muscle wasting disorder, by administering daily doses of alpha-ketoisocaproic acid (ketoleucine) or an appropri... | 06/30/1987 |
| 4418075 | Epoxysuccinyl amino acid derivatives An epoxysuccinyl amino acid derivative of the formula ##STR1## wherein R1 is hydrogen or alkali metal, R2 is isobutyl, R3 is hydrogen or benzyloxycarbonyl, and n is an integer of 5 to 7. The subject compounds exhibit ... | 11/29/1983 |
| 4416885 | Use of isopropylaminopyrimidine in the chemotherapy of muscular dystrophy, myopathy and myotonia A method for the chemotherapy of muscular dystrophy which includes administrating orally an effective amount of 2 isopropylaminopyrimidine.... | 11/22/1983 |
| 4344947 | Use of isopropylaminopyrimidine in the chemotherapy of muscular dystrophy, myopathy and mytonia A method for the chemotherapy of muscular dystrophy which includes administrating an effective amount of 2 isopropylaminopyrimidine.... | 08/17/1982 |
| 4145421 | Treating spastic conditions This invention provides a new myotonolytic use of thiazoline, oxazoline and imidazoline derivatives and novel pharmaceutical compositions for such use.... | 03/20/1979 |
| 3956374 | Aryl-oxo-heptenoic acids Novel 4-phenyl-4-substituted-5-oxo-7-aryl-heptanoic acids are prefaced by either of two synthetic processes. The first method involves the reaction of a 4-phenyl-4-substituted-5-oxo-hexanoic acid with an arylcarboxyaldehyde. The second method involves rea... | 05/11/1976 |
